Grand Hopital De L Est Francilien

At Grand Hopital De L Est Francilien, clinical research in hematologic malignancies focuses on improving outcomes for patients with aggressive blood cancers, including acute lymphoblastic leukemia, acute myeloid leukemia, multiple myeloma, and peripheral T-cell lymphoma. These studies are designed to test new treatment combinations, refine transplant strategies, and strengthen disease control in hard-to-treat settings.

• New immunotherapy approaches for acute lymphoblastic leukemia and acute myeloid leukemia
• Treatment optimization for multiple myeloma in frail or newly diagnosed patients
• Evaluating novel options for peripheral T-cell lymphoma and relapsed disease

The work spans blood cancer therapy, cellular treatment strategies, and immune-based approaches aimed at improving survival and depth of response.

The site also supports a strong portfolio in digestive system cancers, with trials in colon cancer, colorectal cancer, gastric cancer, esophageal cancer, small bowel adenocarcinoma, and hepatocellular carcinoma. Research here is centered on testing new drug combinations, improving adjuvant treatment decisions, and identifying which patients are most likely to benefit from therapy.

• New treatment strategies for colorectal cancer and colon carcinoma
• Immunotherapy-based approaches in gastric and gastro-oesophageal junction adenocarcinoma
• Improving care for hepatocellular carcinoma and small bowel adenocarcinoma

These studies aim to improve cancer control, guide personalized treatment, and evaluate whether newer regimens can extend survival.

Clinical trials in thoracic oncology at this hospital include research in non-small cell lung cancer and large-cell neuroendocrine carcinoma of the lung. The main goal is to assess whether adding new immunotherapy or chemotherapy combinations can improve disease control and survival for people with advanced lung cancer.

• Testing immunotherapy combinations in non-small cell lung cancer
• Evaluating treatment options for large-cell neuroendocrine carcinoma
• Comparing strategies to improve progression-free and overall survival

This area reflects a broader focus on respiratory tract cancers and on finding more effective first-line treatment approaches for advanced disease.

Research in cardiovascular disease includes studies on heart failure, atrial arrhythmia, patent foramen ovale closure, cardiac arrest, and hypertension. These trials are exploring better symptom control, prevention of complications, and improved outcomes in patients with serious heart-related conditions.

• Evaluating new options for heart failure with kidney impairment
• Preventing atrial arrhythmia after patent foramen ovale closure
• Assessing treatments for post-cardiac arrest shock and broader cardiovascular risk

The cardiovascular program emphasizes treatment effectiveness and practical approaches to reduce hospital events and improve recovery.

The clinical trial portfolio also includes infectious diseases and immune system processes, with studies involving bacterial infections, viral diseases, and septic shock. In parallel, the site is investigating ways to improve care for acute infections and severe inflammatory states through better treatment selection and supportive management.

• Studying new approaches for septic shock
• Evaluating therapies for acute vaginal infection
• Supporting research in bacterial and viral disease management

This research area highlights efforts to improve infection control and patient recovery in both common and life-threatening conditions.

The site’s research also extends to metabolic disease, rare disorders, and pediatric conditions, including type 2 diabetes, sickle cell disease, acute osteomyelitis in children, and other congenital or hereditary illnesses. These studies are generally aimed at improving treatment safety, refining dosing in younger patients, and testing more effective care pathways.

• Improving treatment for type 2 diabetes and cardiovascular risk
• Studying supportive care in sickle cell disease
• Comparing outpatient and hospital-based care for pediatric osteomyelitis

This area reflects a commitment to patient-centered care across age groups, with attention to both long-term management and short-term clinical recovery.